49
Participants
Start Date
December 1, 2021
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
Atezolizumab
Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study at the time of participant discontinuation from the parent study closure.
Bevacizumab
Bevacizumab will be administered as directed per the parent study.
Pemetrexed
Pemetrexed will be administered as directed per the parent study.
Paclitaxel
Paclitaxel will be administered as directed per the parent study.
Enzalutamide
Enzalutamide will be administered as directed per the parent study.
Peking Union Medical College Hospital, Beijing
Beijing Cancer Hospital, Beijing
Changchun Cancer Hospital, Changchun
Jilin Cancer Hospital, Changchun
Harbin Medical University Cancer Hospital, Harbin
Shanghai Chest Hospital, Shanghai
The 2nd Hospital of Tianjin Medical University, Tianjin
Jiangsu Cancer Hospital, Nanjing
Cancer Hospital of Shandong First Medical University, Jinan
Tianjin Cancer Hospital, Tianjin
Sir Run Run Shaw Hospital, Hangzhou
Zhejiang Cancer Hospital, Zhejiang
Hunan Cancer Hospital, Changsha
Union Hospital of Tongji Medical College, Dept. of Cancer Center, Wuhan
Henan Cancer Hospital, Zhengzhou
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou
Nanfang Hospital, Southern Medical University, Guangzhou
Hoffmann-La Roche
INDUSTRY